The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia

European Journal of Clinical Pharmacology

Volumn 58, Issue 8, 2002, Pages 501-506

  Koter, M ^a   Broncel, M ^a   Chojnowska Jezierska, J ^a   Klikczynska, K ^a   Franiak, I ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Lipid peroxidation; Membrane fluidity; Statins

Indexed keywords

ATORVASTATIN; CARBON; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID;

ADULT; AGED; ARTICLE; BLOOD RHEOLOGY; CELL MEMBRANE FLUIDITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ERYTHROCYTE MEMBRANE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; MEASUREMENT; MEMBRANE STRUCTURE; PRIORITY JOURNAL; SPIN LABELING; VISCOSITY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; ERYTHROCYTE MEMBRANE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID PEROXIDATION; LIPIDS; MALE; MEMBRANE FLUIDITY; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 0036451225     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0507-9     Document Type: Article

References (45)

1. The long-term intervention with pravastatin in ischemic disease (LIPID) study group: Prevention cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. (1998) N Engl J Med 339:1349-1357
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
3. The Scandinavian Simvastatin Survival Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
4. Davignon J (1998) Methods and endpoint issues in clinical development of lipid-acting agents with pleoiotropic effects. Am J Cardiol 81:17F-24F
5. White C (1999) Pharmacological effects of HMG-CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 39:11-18
6. Brown BG, Zhao XQ, Sacco DE, Albers JJ (1993) Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87:1781-1791
7. Rosenson R, Tangney C (1998) Antithrombic properties of statins. JAMA 279:1643-1647
8. Vaughan CJ, Murphy MB, Buckley BM (1996) Statins do more than just lower cholesterol. Lancet 348:1079-1082
9. Sirtori CR, Colli S (1993) Influences of lipid-modifying agents on hemostasis. Cardiovasc Drugs Ther 7:817-823
10. Martinez M, Vaya A, Marti R, Gil L, Lluch J, Carmena R et al. (1996) Erythrocyte membrane cholesterol/phospholipid changes and haemorheological modifications in familial hypercholesterolemia treated with lovastatin. Thromb Res 83: 375-388
11. Özdemirler G, Selda K, Yusuf O et al. (2001) Lipid and protein oxidation in erythrocyte membranes of hypercholesterolemic subjects. Clin Biochem 34:335-339
12. Schick BP, Schick PK (1985) Cholesterol exchange in platelets, erythrocytes and megakaryocytes. Biochim Biophys Acta 833:281-290
13. Cooper RA (1977) Abnormalities of cell-membrane fluidity in the pathogenesis of disease. N Engl J Med 297:371-377
14. Salonen R, Nyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS et al. (1995) The Kuopio Atheroslerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins and atherosclerotic progression. Circulation 92:1758-1764
15. Hilleman DE, Heineman SM, Foral PA (2000) Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study. Pharmacotherapy 20:819-822
16. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ et al. (2000) Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia. Atherosclerosis 150:421-428
17. Smilde TJ, van den Berkmortel FW, Wollersheim H et al. (2000) The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolemia. Eur J Clin Invest 30:473-480
18. Wang KJ, Ting CT (2001) A randomized, double-blind, placebo-controlled, 8-week study to evaluate the effcacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J 42:725-738
19. Banyai S, Banjai M, Falger J, Jansen M et al. (2001) Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis 159:513-519
20. Otto C, Geiss HC, Donner MG, Parhofer KG, Schwandt P (2000) Influence of atorvastatin versus simvastatin on fibrinogen and other haemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis. Ther Apher 4:244-248
21. Dodge JT, Mitchell C, Hanahan DJ (1963) The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys 100:119-130
22. Lowry OH, Rosenproarg NJ, Farer AL (1953) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
23. Rodriguez-Vico F, Martinez-Cayuela M, Zafra MF, Garcia-Peregrin E, Ramirez H (1991) A procedure for the simultaneous determination of lipid and protein in biomembranes and other biological samples. Lipids 26:77-80
24. Klyszejko-Stefanowicz L (1999) Biochemistry Classes (in Polish). PWN Scientific Publishing, Warszaw, p 30
25. Curtain CC, Gordon LM (1984) ESR-Spectroscopy of Membranes in Membranes Detergents and Receptor Solubilization. Liss AR, New York, pp 177-213
26. Schreier S, Polnaszek CF, Smith IC (1978) Spin labels in membranes. Problems in practice. Biochim Biophys Acta 515:395-436
27. Fung LWM, Johson ME (1984) Recent developments in spin label ESR methodology for biomembranes studies. In: Lee CP (ed) Current topics in bioenergetics. (N Engl J Med, vol 13) Academic Press, New York, pp 107-157
28. Stocks J, Dormandy TL (1971) The autoxidation of human red cell lipids induced by hydrogen peroxide. Br J Hematol 20:95-111
29. Rice-Evans CA, Diploch AT, Symons MCR (1991) Techniques in Free Radical Research. Elsevier, Amsterdam
30. Heinonen TM, Stein E, Weiss SR, Mckenney JM, Davidson M, Shurzinske L et al. (1996) The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study. Clin Ther 18:853-863
31. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The curves study). Am J Cardiol 81:582-587
32. Nawrocki JW, Weiss ST, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ et al. (1995) Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678-682
33. Dwight JF, Mendes-Ribeiro AC, Hendry BM (1996) Effects of HMG-CoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition. Clin Chim Acta 256:53-63
34. Cooper RA, Jandl JH (1968) Bile salts and cholesterol in the pathogenesis of target cell in obstructive jaundice. J Clin Invest 47:809-822
35. Chabanel A, Flamm M, Sung KL, Lee MM, Schachter SL, Chien S (1983) Influence of cholesterol content on red cell membrane viscoelasticity and fluidity. Biophys J 44:171-176
36. Martinez M, Vaya A, Gil L, Mari R, Dalmau J, Aznar J (1998) The cholesterol/phosholipid ratio of the erythrocyte membrane in children with familial hypercholesterolemia. Its relationship with plasma lipids and red blood cell aggregability. Clin Hemorheol Microcirc 18:259-263
37. Muller S, Ziegler O, Donner M, Drouin P, Stoltz JF (1990) Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia. Atherosclerosis 83:231-237
38. Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan U (1994) Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 43:11-17
39. Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U (1992) Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolemia. Br J Clin Pharmacol 34:427-430
40. Lijnen P, Celis H, Fagard R, Staessen J, Amery A (1994) Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 12:59-64
41. Van Doormaal JJ, Bos WJ, Muskiet FA, Doorenbos H (1989) Simvastatin influences linoleic acid metabolism. Pharm Weekbl Sci 11:134-135
42. Rabini RA, Polenta M, Staffolani R, Tocchini M, Signore R, Testa I et al. (1993) Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocytes membranes. Exp Mol Pathol 59:51-57
43. Simon E, Paul JL, Atger V, Simon A, Moatti N (1998) Erythrocyte antioxidant status in asymptomatic hypercholesterolemic men. Atherosclerosis 138:375-381
44. Pfafferott C, Meiselman HJ, Hochstein P (1982) The effect of malonyldialdehyde on erythrocyte deformability. Blood 59:12-15
45. Aviram M, Rosenblat M, Bisgaier CL, Newton RS (1998) Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138:271-280